Amyndas Pharmaceuticals

38 posts

Amyndas Pharmaceuticals banner
Amyndas Pharmaceuticals

Amyndas Pharmaceuticals

@Amyndas

#Amyndas is a pharmaceutical company developing #complement #therapeutics (#compstatins etc) for inflammatory diseases and disorders.

Katılım Aralık 2017
20 Takip Edilen142 Takipçiler
Amyndas Pharmaceuticals
Amyndas Pharmaceuticals@Amyndas·
Excited to announce that @Amyndas is a partner of the #HorizonEurope-funded project @fibrotarget which aims to advance our understanding of #IBD #fibrosis & #fibrostenosis and explore new targets for disease diagnosis and therapy
FIBROTARGET@fibrotarget

🎉We're proud to announce that @fibrotarget is now in action🎉 This #HorizonEurope project aims to advance inflammatory bowel disease (#IBD) diagnosis and therapies🔬 You can learn more about the 5-year initiative below in our LIVE website🌐 fibrotarget.eu #fibrosis

English
0
0
1
601
Amyndas Pharmaceuticals
Amyndas Pharmaceuticals@Amyndas·
We are thrilled to announce positive Phase 2 results for AMY-101 in adults with periodontal inflammation and gingivitis. Our study met both its primary and secondary endpoints with prominent resolution of periodontal inflammation. amyndas.com/amyndas-period…
English
1
3
11
0
Amyndas Pharmaceuticals
Amyndas Pharmaceuticals@Amyndas·
Check out our new EXCITING data on the efficacy of AMY-101 in #COVID19 patients supporting the GREAT potential of #complement #C3 inhibition for a broad therapeutic effect. #AMY101 #thromboinflammation
John D. Lambris, Ph.D.@LambrisJD

Check out our new study comparing C3 inhibition with C5 blockade in #COVID19: our early clinical findings offer important insight into the differential mechanistic basis of C3 & C5 inhibition and support a broader therapeutic profile of #AMY101 in COVID-19 #thromboinflammation

English
0
3
7
0
Amyndas Pharmaceuticals
Amyndas Pharmaceuticals@Amyndas·
Ευχαριστούμε τη Θεοδώρα Τσώλη και το @tovimagr για την συνέντευξη και εμπεριστατωμένη παρουσίαση του κλινικού προγράμματος αξιολόγησης της θεραπευτικής δράσης του αναστολέα C3 #ΑΜΥ101 σε ασθενείς #COVID19 tovima.gr/2020/06/15/sci…
Ελληνικά
0
2
4
0
Amyndas Pharmaceuticals retweetledi
John D. Lambris, Ph.D.
John D. Lambris, Ph.D.@LambrisJD·
Κορωνοϊός -Εγκριση από τον Αμερικανικό Οργανισμό Φαρμάκων στην ελληνική «Αμύντας» για κλινική δοκιμή σε ασθενείς iefimerida.gr/ygeia/koronoio…
Ελληνικά
0
1
1
0
Amyndas Pharmaceuticals
Amyndas Pharmaceuticals@Amyndas·
We are thrilled to announce that the most advanced complement C3 inhibitor #AMY101 has received FDA approval for a randomized Phase 2 trial in #COVID19 patients with ARDS. AMY-101 suppresses cytokine release and thromboinflammation in COVID-19. amyndas.com/covid-19/
English
1
9
23
0
Amyndas Pharmaceuticals
Amyndas Pharmaceuticals@Amyndas·
Prospects have never been better for testing novel C3-targeted therapeutics in ocular indications #AMD Check out this new paper by our founder @LambrisLab reporting on the promising ocular PK profile of a fourth-generation #compstatin analog clinically developed by @Amyndas
John D. Lambris, Ph.D.@LambrisJD

Happy to share our recent paper on the promising #ocular PK and tissue distribution profile of a fourth-generation #compstatin-based #C3 inhibitor This work could lead to more effective ocular #therapeutics for diseases fueled by C3 dysregulation @Penn @Amyndas

English
0
1
2
0
Amyndas Pharmaceuticals
Amyndas Pharmaceuticals@Amyndas·
We’re thrilled that our Founder @Penn Prof John Lambris is on the #WebofScience #HighlyCitedResearchers 2019 list for the 2nd consecutive year! We’re grateful for his contributions in helping us develop the most advanced #ComplementTherapeutics #amyndas @ComplementSoc @LambrisLab
Dimitris Mastellos@dmastellos

Congratulations to @Penn Prof John Lambris @LambrisLab for being recognized as a #WebofScience Highly Cited Researcher for a second consecutive year! We are all so very proud of you! #HighlyCited2019 @PennMedNews @webofscience @clarivate @ComplementSoc @AegeanConf

English
1
1
6
0
Amyndas Pharmaceuticals retweetledi
Nature Reviews Drug Discovery
Nature Reviews Drug Discovery@NatRevDrugDisc·
Our September issue is out! Read about targeting immunometabolism, complement therapeutics, oncolytic virotherapy, harnessing machine learning for cellular imaging and more go.nature.com/2lVOs5B
Nature Reviews Drug Discovery tweet media
English
0
4
14
0

Keşfet

@fibrotarget @LambrisJD @webofscience @PennMedicine @SanRaffaeleMI @NCSR_Demokritos @Columbia @uni_ulm